相关实验视频
Updated: Jan 14, 2026

07:16
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
14.6K
PACT是前列腺癌细胞增殖的必要条件
Dianne J Beveridge1, Andrew J Woo1,2, Kirsty L Richardson1
1Laboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, and Centre for Medical Research, The University of Western Australia, Crawley, WA, 6009, Australia.
Scientific reports
|October 21, 2025
概括
PACT蛋白促进前列腺癌 (PCa) 细胞的增殖. 耗尽PACT会减少PCa细胞的生长,并可能为前列腺癌治疗提供新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 病毒学 病毒学
背景情况:
- PACT (PRKRA基因) 是一种RNA结合蛋白,参与抗病毒防御和核受体基因调节.
- 之前的工作确定了PACT在调节核受体调节基因表达中的作用.
研究的目的:
- 为了研究PACT在前列腺癌 (PCa) 发病过程中的作用.
- 探索PACT作为PCa的潜在治疗点.
主要方法:
- 在PCa细胞系中使用PACT枯竭的功能丧失研究.
- RNA测序分析以确定PACT调节的基因和途径.
- 特定基因的siRNA介导淘汰和细胞增殖的评估.
- 对雄激素受体 (AR) 信号和PSA基因表达的分析.
主要成果:
- PACT的耗尽减少了PCa细胞的增殖,但保持了活力.
- RNA-seq揭示了PACT淘汰细胞中细胞周期,线粒体功能和NR响应通路的下调.
- 低调基因,包括KLK3 (PSA),在PACT耗尽后也减少了细胞生长.
- PACT或PSA降低诱导的G0/G1细胞周期停止.
- 在对荷尔蒙刺激和AR抗剂的反应中,PACT淘汰赛细胞显示出改变的PSA基因表达.
结论:
- PACT在前列腺癌中起到了促进生殖的作用.
- 针对PACT或PACT下调基因 (如PSA) 的治疗策略显示出PCa治疗的前景.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K

